Advanced APMs and the Emerging Role of Immuno-Oncology Agents: Balancing Innovation and Value
The shift to value-based care, concurrent with innovations in immune-based care, will create challenges in oncology. What should be the physician and manufacturer responsibility during these changing times?
Immuno-Oncology 2016 and Beyond: The Opportunities, Challenges, and Risks
The translation of immuno-oncology agents from the research to the practice arena may provide significant clinical benefit to patients with difficult-to-treat malignancies. The further development and marketing of these agents could escalate the discussion on care equity in a time of constrained resources.
2 Clarke Drive Cranbury, NJ 08512